WO2012169842A2 - 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 - Google Patents
차나무 잎에서 분리한 신규 락토바실러스 플란타룸 Download PDFInfo
- Publication number
- WO2012169842A2 WO2012169842A2 PCT/KR2012/004569 KR2012004569W WO2012169842A2 WO 2012169842 A2 WO2012169842 A2 WO 2012169842A2 KR 2012004569 W KR2012004569 W KR 2012004569W WO 2012169842 A2 WO2012169842 A2 WO 2012169842A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- apsulloc
- strain
- lactobacillus plantarum
- lactic acid
- kctc3108
- Prior art date
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 90
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 90
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 claims abstract description 37
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 72
- 239000004310 lactic acid Substances 0.000 claims description 36
- 235000014655 lactic acid Nutrition 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 21
- 239000003613 bile acid Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 9
- 235000006468 Thea sinensis Nutrition 0.000 claims description 3
- 235000021107 fermented food Nutrition 0.000 claims description 2
- 244000052707 Camellia sinensis Species 0.000 claims 1
- 235000013305 food Nutrition 0.000 description 29
- 230000004083 survival effect Effects 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 241000894006 Bacteria Species 0.000 description 18
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 16
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 16
- 229920001817 Agar Polymers 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 244000269722 Thea sinensis Species 0.000 description 12
- 230000003115 biocidal effect Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 235000013616 tea Nutrition 0.000 description 12
- 239000008272 agar Substances 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 8
- 229930182843 D-Lactic acid Natural products 0.000 description 8
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 8
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 8
- 108090001060 Lipase Proteins 0.000 description 8
- 229940022769 d- lactic acid Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 235000010356 sorbitol Nutrition 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241000607762 Shigella flexneri Species 0.000 description 7
- 229960000484 ceftazidime Drugs 0.000 description 7
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 229960000564 nitrofurantoin Drugs 0.000 description 7
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 102000053187 Glucuronidase Human genes 0.000 description 6
- 108010060309 Glucuronidase Proteins 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229960002227 clindamycin Drugs 0.000 description 6
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 101710180684 Beta-hexosaminidase Proteins 0.000 description 5
- 101710124976 Beta-hexosaminidase A Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000186684 Lactobacillus pentosus Species 0.000 description 5
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 5
- 101710081801 Protein O-GlcNAcase Proteins 0.000 description 5
- 101710199095 Putative beta-hexosaminidase Proteins 0.000 description 5
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 102000005840 alpha-Galactosidase Human genes 0.000 description 5
- 108010030291 alpha-Galactosidase Proteins 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000006150 trypticase soy agar Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 4
- IZSRJDGCGRAUAR-MROZADKFSA-M 5-dehydro-D-gluconate Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IZSRJDGCGRAUAR-MROZADKFSA-M 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N Arbutin Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 241000193755 Bacillus cereus Species 0.000 description 4
- 101710195319 Beta-galactosidase 5 Proteins 0.000 description 4
- 101710099629 Beta-glucosidase 3 Proteins 0.000 description 4
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 4
- 239000004386 Erythritol Substances 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 4
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 4
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- PYMYPHUHKUWMLA-WISUUJSJSA-N aldehydo-L-xylose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WISUUJSJSA-N 0.000 description 4
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 4
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 4
- 102000019199 alpha-Mannosidase Human genes 0.000 description 4
- 108010012864 alpha-Mannosidase Proteins 0.000 description 4
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 229960000271 arbutin Drugs 0.000 description 4
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019414 erythritol Nutrition 0.000 description 4
- 229940009714 erythritol Drugs 0.000 description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 239000000174 gluconic acid Substances 0.000 description 4
- 235000012208 gluconic acid Nutrition 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 229960000367 inositol Drugs 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 4
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010093965 Polymyxin B Proteins 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229960002182 imipenem Drugs 0.000 description 3
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 3
- 235000021109 kimchi Nutrition 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920000024 polymyxin B Polymers 0.000 description 3
- 229960005266 polymyxin b Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 3
- 229960001082 trimethoprim Drugs 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- 241000186781 Listeria Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000013630 prepared media Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 241000209507 Camellia Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- 108010001539 D-lactate dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 101001004672 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Probable L-lactate dehydrogenase Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- PYMYPHUHKUWMLA-VPENINKCSA-N aldehydo-D-xylose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VPENINKCSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical class OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/56—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- the present invention relates to a novel Lactobacillus plantarum isolated from tea leaves.
- Tea for drinking is inactivating and removing water from oxidases present in the shoots or leaves of Camellia sinensis of the Camellia family. These teas contain vitamins, caffeine, tannins, flavonoids and essential oils, and are widely used in various fields such as food.
- the present invention seeks to provide a novel Lactobacillus plantarum strain.
- a composition comprising the novel Lactobacillus plantarum strain or its culture.
- One aspect of the invention provides a Lactobacillus plantarum APsulloc 331261 strain.
- One aspect of the present invention provides a Lactobacillus Planta room (Lactobacillus plantarum) APsulloc 331263 strain.
- One aspect of the invention provides a Lactobacillus plantarum APsulloc 331266 strain.
- One aspect of the invention provides a Lactobacillus plantarum APsulloc 331269 strain.
- compositions comprising one or more of Lactobacillus plantarum APsulloc 331261 strain, APsulloc 331263 strain, APsulloc 331266 strain, and APsulloc 331269 strain or a culture thereof.
- the novel Lactobacillus plantarum strain according to the present invention Since the novel Lactobacillus plantarum strain according to the present invention has excellent acid resistance, it can survive in the stomach ( ⁇ ) when ingested as food, and furthermore, the intestinal reach rate can be high.
- the Lactobacillus plantarum strain according to the present invention is excellent in bile acid performance, and therefore has excellent intestinal fixation ability.
- the Lactobacillus plantarum strain according to the present invention is excellent in antimicrobial activity and excellent in inhibiting harmful bacteria.
- the Lactobacillus plantarum strain according to the present invention has a low ratio of D-lactic acid in the produced lactic acid compared to the existing Lactobacillus plantarum, so that adults or infants vulnerable to lactic acid can be freely ingested.
- the Lactobacillus plantarum strain according to the present invention produces a smaller amount of lactic acid than the existing Lactobacillus plantarum, so that the food has a soft taste when the food is fermented using the same. Therefore, the novel Lactobacillus plantarum strain according to the present invention can be widely used in various fields, for example, the food field.
- Lactic acid bacteria refers to bacteria that produce lactic acid by breaking down sugars such as glucose and are also referred to as lactic acid bacteria. Lactic acid produced by lactic acid fermentation of lactic acid bacteria can inhibit the growth of pathogens and harmful bacteria, and this property is used for the production of foods such as dairy products, kimchi and brewed foods. In addition, lactic acid bacteria live in the intestines of mammals to prevent abnormal fermentation by various bacteria, so it is an important bacterium that is also used as a formal agent.
- Lactobacillus plantarum is a strain belonging to lactic acid bacteria is known to grow mainly when the fermentation of kimchi has a lot of sour taste.
- the optical isomers of lactic acid produced are D-type and L-type. Since Lactobacillus plantarum can be widely used in various foods requiring fermentation, if Lactobacillus plantarum having excellent acid resistance, bile acid performance and antibacterial activity is developed, it may be usefully used.
- One aspect of the invention provides a Lactobacillus plantarum APsulloc 331261 (Accession Number: KCCM11179P) strain.
- One aspect of the invention provides a Lactobacillus plantarum APsulloc 331263 (Accession Number: KCCM11180P) strain.
- One aspect of the invention provides a Lactobacillus plantarum APsulloc 331266 (Accession Number: KCCM11181P) strain.
- One aspect of the invention provides a Lactobacillus plantarum APsulloc 331269 (Accession Number: KCCM11182P) strain.
- At least one of Lactobacillus plantarum APsulloc 331261, APsulloc 331263, APsulloc 331266, and APsulloc 331269 according to the present invention belongs to Lactobacillus plantarum as a strain isolated from Camellia sinensis leaves.
- the Lactobacillus plantarum strain according to the present invention comprises the steps of pickling the tea leaves with a salt of 5 to 15% by weight relative to the tea leaf weight; Mixing the pickled tea leaves with a sugar solution, for example 0.1% to 3% of fructo oligosaccharides, and incubating at 25 to 35 ° C. for 1 to 5 days; And it can be separated by a method comprising the step of taking the culture medium to less than pH 5 and incubating for 1 to 5 days at 25 to 35 °C anaerobic conditions.
- At least one of Lactobacillus plantarum APsulloc 331261, APsulloc 331263, APsulloc 331266, and APsulloc 331269 has excellent acid resistance.
- a lactic acid bacterium for example, Lactobacillus plantarum is taken as a probiotic
- a high intestinal attainment rate is preferable in order to exert an effect peculiar to lactic acid bacteria.
- gastric acid secretion requires a high survival rate in the lower pH.
- the fasting pH of the stomach is about 1.2 to 2, but the intake of food pH is known to be about 2-3.
- Lactobacillus plantarum strains according to the present invention have excellent acid resistance at pH 2 to 4, specifically pH 2 to 3.5 or pH 2.5 to 4, more specifically pH 2.5 to 3.5, even more specifically at pH 2.5 to 3 Has On the other hand, when ingesting food, the average stomach residence time of the food is known to be about 1 to 3 hours.
- the Lactobacillus plantarum strain according to the present invention is pH 2 to 4, specifically pH 2 to 3.5 or pH 2.5 to 4, more specifically pH 2.5 to 0.5 hours to 5 hours, specifically 1 to 4 hours. 3.5, even more particularly have good acid resistance at pH 2.5 to 3. Therefore, the Lactobacillus plantarum strain according to the present invention has a high intestinal attainment rate when ingested as food because it can survive even at low pH of the stomach during the stomach retention period.
- Lactobacillus plantarum strain according to one aspect of the present invention has excellent bile acid capacity. Food passing through the stomach is delivered to the small intestine, at which time bile acids are secreted to help digest food. Strains that are highly resistant to bile acids are known to have good intestinal fixation ability. The Lactobacillus plantarum strain according to one aspect of the present invention is excellent in the intestinal fixability because it has excellent bile acid performance.
- Lactobacillus plantarum strain has the ability to produce lactic acid.
- lactic acid produced by lactic acid bacteria includes L-type and D-type.
- D-lactic acid has a slower metabolic rate than L-lactic acid, and thus, high concentrations of D-lactic acid in the blood may cause lactic acid poisoning. Therefore, it is desirable that adults and infants who are vulnerable to lactic acid should not consume lactic acid bacteria that produce large amounts of D-lactic acid.
- the Lactobacillus plantarum strain may produce lactic acid having a D-type of 75% or less, specifically 70% or less, and more specifically 65% or less of the produced lactic acid.
- Lactobacillus plantarum strain according to another aspect of the present invention is 17.5 g / L or less, specifically 17 g / L or less, more specifically 16.5 g / L or less, more specifically 15 g / L or less, more More specifically 14.5 g / L or less, even more specifically 14 g / L or less, even more specifically 13.5 g / L or less lactic acid.
- the Lactobacillus plantarum strain according to the present invention generates lactic acid having a lower D-type ratio than the existing Lactobacillus plantarum, so that adults or infants vulnerable to lactic acid can be freely ingested.
- the amount of lactic acid produced is lower than conventional Lactobacillus plantarum, so when the food is fermented by using the food may have a softer taste.
- One aspect of the invention provides an extract or culture of one or more of Lactobacillus plantarum APsulloc 331261 strain, APsulloc 331263 strain, APsulloc 331266 strain and APsulloc 331269 strain.
- Another aspect of the present invention provides a composition comprising one or more of Lactobacillus plantarum APsulloc 331261 strain, APsulloc 331263 strain, APsulloc 331266 strain and APsulloc 331269 strain, extracts thereof, or a culture thereof.
- One aspect of the present invention provides a food composition comprising one or more of the Lactobacillus plantarum APsulloc 331261 strain, APsulloc 331263 strain, APsulloc 331266 strain, and APsulloc 331269 strain, extracts thereof, or a culture thereof.
- the food composition may be a health food composition, it may be a fermented food composition that requires fermentation, such as tea, dairy products, kimchi, brewed foods.
- the formulation of the food composition is not particularly limited, but may be, for example, formulated into tablets, pills, soft and hard capsules, granules, drinks, caramels, diet bars, tea bags, and the like.
- the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
- Determination of the dosage of the active ingredient is within the level of those skilled in the art, and its daily dosage is, for example, Lactobacillus plantarum 10 5 to 10 13 CFU / day, more specifically 10 6 to 10 10 CFU / day.
- the present invention is not limited thereto and may vary depending on various factors such as age, health condition, complications, etc. of the subject to be administered.
- One aspect of the present invention provides a cosmetic composition
- a cosmetic composition comprising one or more of the Lactobacillus plantarum APsulloc 331261 strain, APsulloc 331263 strain, APsulloc 331266 strain, and APsulloc 331269 strain, extracts thereof, or a culture thereof.
- the cosmetic composition may be provided in any formulation suitable for topical application.
- it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a foam, or an aerosol composition.
- Compositions of such formulations may be prepared according to conventional methods in the art.
- the cosmetic composition may contain, in addition to the above-mentioned materials, other ingredients that can give a synergistic effect to the main effect within a range not impairing the main effect.
- the cosmetic composition according to the present invention may include a substance selected from the group consisting of vitamins, polymer peptides, polymer polysaccharides and sphingolipids.
- the cosmetic composition according to the present invention may include a moisturizer, an emulsifier, a surfactant, a ultraviolet absorber, a preservative, a fungicide, an antioxidant, a pH adjuster, organic and inorganic pigments, flavoring agents, cooling agents or limiting agents. .
- the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition. have.
- One aspect of the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising one or more of the Lactobacillus plantarum APsulloc 331261 strain, APsulloc 331263 strain, APsulloc 331266 strain, and APsulloc 331269 strain, extracts thereof, or a culture thereof.
- the pharmaceutical composition may be used for the prevention or treatment of intestinal diseases, such as irritable bowel syndrome, constipation, diarrhea and the like.
- compositions according to one aspect of the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.
- Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, granules, solutions, emulsions or pellets, but are not limited thereto. It is not.
- Formulations for parenteral administration may be, but are not limited to, solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches or sprays.
- the formulations can be readily prepared according to conventional methods in the art and include surfactants, excipients, hydrating agents, emulsifiers, suspending agents, salts or buffers for controlling osmotic pressure, colorants, spices, stabilizers, preservatives, preservatives or Other commercially available auxiliaries can be used as appropriate.
- the active ingredient of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Dosage determination based on these factors is within the level of one skilled in the art, the daily dosage of which is for example from 0.1 mg / kg / day to 5000 mg / kg / day, more specifically from 50 mg / kg / day to 500 mg / kg May be, but is not limited to.
- Lactobacillus plantarum APsulloc 331261, APsulloc 331263, APsulloc 331266, and APsulloc 331269, as of March 28, 2011, are located at the Korea Microbiological Conservation Center located at 361-221 Hongje 1-dong, Seodaemun-gu, Seoul, Korea. of Microorganisms) were deposited with microbial accession numbers KCCM11179P, KCCM11180P, KCCM11181P and KCCM11182P, respectively.
- tea leaves 200g are washed twice with distilled water to remove foreign substances. Drain the washed tea leaves and mix with salt equivalent to 8% of tea leaves weight and leave at room temperature for 3 hours.
- the salted tea leaves are mixed with 1000 mL of a 1% fructo oligosaccharide solution and incubated in a 32 ° C. incubator for 3 days. Three days confirmed that the pH of the culture solution drop to less than 5 and less than pH 5 after taking them deep nose galactosidase is cultured in MRS agar Bashile ® (Difco Lactobacilli MRS Agar ®) medium. At this time, the culture takes 32 days, incubated in an anaerobic chamber for 2 days, and takes colonies showing white colonies.
- MRS agar Bashile ® Difco Lactobacilli MRS Agar ®
- Lactobacillus plantarum APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 were isolated from the leaves of the tea tree.
- APsulloc 331263 isolated in Example 1 was streaked on an MRS agar plate and incubated at 37 ° C. for 2 days. A single colony obtained was inoculated in 10 mL of MRS broth and incubated overnight at 37 ° C. to prepare a Lactobacillus plantarum strain culture. Lactobacillus plantarum strain cultures are prepared in substantially the same manner for APsulloc 331263, APsulloc 331266 and APsulloc 331269, respectively.
- APsulloc 331261 strain culture solution prepared as in (1) was inoculated with 0.5% of 10 mL MRS broth and incubated overnight at 37 ° C. The culture solution was centrifuged at 8,000 rpm for 5 minutes, the supernatant was removed, only the cells were collected, and suspended by adding 2 mL of 0.85% saline buffer. Since the API 50CHL kit (Biomerieux) was used according to the manufacturer's protocol. The details are as follows.
- the suspension amount of the strain was gradually added to 5 mL of API suspension medium (MecFarland Standard 2) (Biomerieux) to measure the amount of suspension required for turbidity. Two times the amount of the measured suspension was added to 10 mL of API 50CHL medium, followed by shaking. After the mixture was placed in a cupule containing different substrates, mineral oil was dropped one by one, incubated at 37 ° C. for 2 days, and then the sugar fermentation pattern was analyzed. The sugar fermentation patterns were analyzed in substantially the same manner for strain cultures of APsulloc 331263, APsulloc 331266 and APsulloc 331269, respectively.
- APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 all Lactobacillus Planta room (Lactobacillus plantarum) match degree (% index) is indicated by more than 99% Lactobacillus Planta room (Lactobacillus plantarum) for You can see that belongs to.
- APsulloc 331261 has different properties of ⁇ -methyl-mannoside and raffinose
- APsulloc 331263 is ⁇ -methyl-mannoside
- raffinose and D- D-turanose uses different properties
- APsulloc 331266 has different properties of ⁇ -methyl-mannoside and raffinose
- APsulloc 331269 uses L-arabinose and raffinose. Because of their different properties, they can be confirmed that they are all different from the standard strain.
- APsulloc 331261 strain culture solution prepared as in (1) was inoculated with 0.5% of 10 mL MRS broth and incubated overnight at 37 ° C. The culture solution was centrifuged at 8,000 rpm for 5 minutes, the supernatant was removed, only the cells were collected, and suspended by adding 2 mL of 0.85% saline buffer. Thereafter, using the API ZYM kit (Biomerieux) was performed according to the manufacturer's protocol. The details are as follows.
- the suspension amount of the strain was gradually added to 5 mL of API suspension medium (MecFarland Standard 2) (Biomerieux) to measure the amount of suspension required for turbidity. Two times the measured amount of suspension was added to 10 mL of API 50CHL medium, followed by shaking. 65 ⁇ l of the mixture was added to each cupule and incubated at 37 ° C. for 4 hours. ZYM A reagent and ZYM B reagent were dropped one drop into each Kupul, and after 5 minutes, scored from 0 to 5 according to the intensity of color, and 3 or more was determined as positive.
- API suspension medium MecFarland Standard 2
- ZYM A reagent and ZYM B reagent were dropped one drop into each Kupul, and after 5 minutes, scored from 0 to 5 according to the intensity of color, and 3 or more was determined as positive.
- Enzyme activity patterns were analyzed for APsulloc 331263, APsulloc 331266, and APsulloc 331269 strain cultures in substantially the same manner.
- APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 are all standard strains (KCTC3108), acid phosphatease, naphthol-AS-BI-phosphohydrolase (Naphthol-AS-). There were differences in the enzymatic activity of BI-phosphohydrolase, ⁇ -galactosidase and N-acetyl- ⁇ -glucosaminidase. Therefore, it can be seen that APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 are all different from the standard strain.
- APsulloc 331261, APsulloc 331263, APsulloc 331266, and APsulloc 331269 are also known as ⁇ -glucuronidase ( ⁇ -), which is known to be one of the representative carcinogenic enzymes that can induce cancer by acting on carcinogens in the intestine and transforming them into carcinogens. negative for glucuronidase) activity.
- ⁇ - ⁇ -glucuronidase
- APsulloc 331263 inhibits the activity of ⁇ -glucosidase. Therefore, it can be seen that APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 may all be used in food compositions.
- Antibiotic resistance was evaluated in the same manner for APsulloc 331263, APsulloc 331266 and APsulloc 331269 strain cultures, respectively.
- Antibiotic susceptibility assessment disc concentrations and criteria are shown in the table below.
- Antimicrobial resistance evaluation results of APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 compared to Lactobacillus plantarum strain (KCTC3108) as standard strains are as follows. Table 11: APsulloc 331261 and APsulloc 331263, Table 12: APsulloc 331266 and APsulloc 331269.
- the standard strain (KCTC3108) and APsulloc 331261 showed differences in the antibiotic resistance patterns of ceftazidime, clindamycin, and nitrofurantoin, and APsulloc 331263 was ceftazidime. (ceftazidime) and nitrofurantoin showed differences in antibiotic resistance patterns.
- the standard strain (KCTC3108) and APsulloc 331266 showed differences in antibiotic resistance patterns of ceftazidime, nitrofurantoin and peniciilin, while APsulloc 331269 cefazidime and clindamycin Clindamycin, nitrofurantoin and peniciilin showed differences in antibiotic resistance patterns. Therefore, it can be seen that APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 are all different from the standard strain.
- APsulloc 331261, APsulloc 331263, APsulloc 331266, and APsulloc 331269 all belong to the Lactobacillus plantarum and differ from the Lactobacillus plantarum standard strain (KCTC3108). It can be seen that the new strain.
- APsulloc 331261 strain culture was inoculated in 10 mL of MRS broth and incubated overnight at 37 ° C. The pH was adjusted to 2.0, 2.5, 3.0, 3.5 with HCl, and then, 50 ⁇ l of the culture solution was inoculated into 5 mL of sterilized MRS broth, followed by incubation at 37 ° C. for 1 hour. One hour later, the cells were diluted with peptone saline buffer to measure the number of bacteria per mL. After measuring the number of bacteria in the culture solution was multiplied by 0.01 as a control (Control), the survival rate was calculated by the control bacteria as 100%.
- APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 all showed higher survival than standard strains at pH 2.5 to 3.5. That is, it can be seen that the Lactobacillus plantarum has excellent acid resistance. Considering the pH of the stomach when the food intake is 2-3, it can be seen that the survival rate of the stomach will be high if the Lactobacillus plantarum is included in the food composition.
- APsulloc 331261 culture was inoculated 0.5% in 10 mL of MRS broth and incubated overnight at 37 °C. After inoculating 50 ⁇ l of the culture solution adjusted to pH 2.5 with HCl to 5 mL of sterilized MRS broth, the cells were incubated at 37 ° C. for 3 hours. After 1 and 3 hours, the cells were diluted with peptone saline buffer and the number of bacteria per mL was measured. After measuring the culture number of the culture medium was multiplied by 0.01 as a control (control), the control cell was counted to 100% survival rate.
- APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 all have a higher survival rate than the standard strain even after 1 hour and 3 hours at pH 2.5. That is, the Lactobacillus plantarum strains can be confirmed that all have excellent acid resistance for a long time. Considering that the average gastric residence time is 1 to 3 hours when the food is ingested, it can be seen that if the Lactobacillus plantarum strains are included in the food composition, the survival rate will be high even during gastric residence.
- APsulloc 331261, APsulloc 331263, APsulloc 331266, and APsulloc 331269 are all able to survive the low pH of the stomach during the residence period of the stomach, so they can survive in the stomach when consumed as food, furthermore, the intestinal reach rate is high.
- APsulloc 331261 culture was inoculated 0.5% in 10 mL of MRS broth and incubated overnight at 37 °C. Ox bile (ox gall) was added 0.3% and 0.5% respectively to prepare a MRS agar plate. As a control, MRS agar without ox bile was used. The strain culture solution was diluted and incubated for 2 days at 37 ° C. after smearing in MRS agar medium. After counting each colony, the survival rate (%) of APsulloc 331261 was calculated using the control cell number as 100%.
- strain cultures of APsulloc 331263, APsulloc 331266, and APsulloc 331269 were also evaluated for bile acid performance in substantially the same manner, respectively, and the results are shown in the table below.
- APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 all showed excellent bile acid resistance. Since strains with excellent bile acid capacity are known to have excellent intestinal fixation ability, it can be seen that APsulloc 331261, APsulloc 331263, APsulloc 331266 and APsulloc 331269 all have excellent intestinal fixation ability and intestinal reach rate.
- APsulloc 331261 culture was inoculated 0.5% in 10 mL of MRS broth and incubated overnight at 37 °C. The culture was centrifuged at 8000 rpm for 15 minutes to recover only the supernatant. The recovered supernatant was treated at 80 ° C. for 15 minutes to stop the enzyme reaction. The supernatant heat-treated with distilled water was diluted 100 times. D-lactic acid / L-lactic acid UV method kit (R-biopharm) was used according to the manufacturer's protocol. The details are as follows.
- kit solution 1 glyciglycine buffer / L-glutamate
- solution 2 NAD solution
- GPT suspension solution 3 0.02 mL
- 0.1 mL each of the supernatant prepared above was added to the cuvette.
- 1 mL of tertiary distilled water and 0.9 mL of tertiary distilled water were added to the control group.
- the absorbance (A1) was measured at 340 nm after 5 minutes.
- 0.02 mL of D-LDH solution 4 each, the mixture was mixed well and reacted for 30 minutes, and the absorbance (A2) was measured at 340 nm.
- strain cultures of APsulloc 331263, APsulloc 331266 and APsulloc 331269 were also evaluated for the lactic acid production ability in substantially the same manner, respectively, and the results are shown in the table below.
- APsulloc 331263, APsulloc 331266 and APsulloc 331269 all produced both D-lactic acid and L-lactic acid.
- the total amount of lactic acid produced was lower than that of the standard strain, and the ratio of D-lactic acid in the produced lactic acid was small. Therefore, the food containing the Lactobacillus plantarum strains can be freely ingested even adults and infants vulnerable to lactic acid, the food may have a softer taste when fermenting the food using the Lactobacillus plantarum strains.
- APsulloc 331261 culture was inoculated 0.5% in 10 mL of MRS broth and incubated overnight at 37 °C. After sterile MRS agar was dispensed into 15 mL petri dishes, 1 ⁇ l of the APsulloc 331261 culture solution was added dropwise, and then cultured at 37 ° C. for 24 hours.
- Shigella flexneri Shigella flexneri
- Tryptic soy agar Tryptic soy agar
- BHI soft agar agar 1%) was sterilized and cooled to 45 ⁇ 50 °C and then inoculated with Shigella flexneri (1% Shigella flexneri ) culture.
- Shigella flexneri culture was hardened by stacking 10 mL of the culture on the APsulloc331261 medium. After incubation at 37 ° C. for 24 hours, the size of the clear zone was measured. The results of comparing Lactobacillus plantarum strain (KCTC3108) as a standard strain are shown in the table below.
- APsulloc 331261 can be confirmed that the antibacterial effect on Shigella flexneri ( Shigella flexneri ) than the standard strain.
- APsulloc 331266 culture was inoculated 0.5% in 10 mL MRS broth overnight incubation at 37 °C.
- BHI soft agar (agar 1%) was sterilized and cooled to 45 ⁇ 50 °C and then inoculated with 1% of Listeria monocytogenes and Bacillus cereus culture. Petri dishes were dispensed in 15 mL and cooled for 1 hour to prepare a medium. Sterilized MRS soft agar (1% agar) was layered and solidified on the prepared medium by 5 mL. APsulloc 331266 culture solution was added dropwise to the cultured medium and 5 ⁇ l each was dried. After incubation at 37 ° C. for 24 hours, the size of the clear zone was measured. The results of comparing Lactobacillus plantarum strain (KCTC3108) as a standard strain are shown in the table below.
- APsulloc 331266 can be confirmed that the antibacterial effect against Listeria monocytogenes and Bacillus cereus than the standard strain.
- APsulloc 331269 culture was inoculated 0.5% in 10mL MRS broth overnight incubation at 37 °C. The culture solution was centrifuged at 8000 rpm for 5 minutes and only the supernatant was recovered. 10 mL of the supernatant was prepared by sterilization with a 0.22 ⁇ L syringe filter.
- Salmonella typhimurium (Salmonella typhimurium), and stapling Pyrococcus fringing mouse (Staphylococcus aureus), each Tryptic Soy agar and plated on (Tryptic soy agar) after overnight incubation at 37 °C inoculated colonies on BHI broth overnight Incubated.
- BHI agar was sterilized and put in 20 mL of Petri dishes to cool to prepare a medium.
- Salmonella typhimurium and Staphylococcus aureus cultures were diluted 50-fold with sterile physiological saline and then evenly spread on the prepared medium with a sterile swab.
- the sterile paper discs were raised and 100 ⁇ l of the APsulloc 331269 culture supernatant prepared above was dropped onto the paper discs. After standing at room temperature for about 3 hours to be absorbed and incubated at 37 °C 24 hours. The size of the clear zone was measured, and the results of comparing Lactobacillus plantarum strain (KCTC3108) as a standard strain are shown in the table below.
- APsulloc 331269 can be confirmed that the antibacterial effect against Salmonella typhimurium and Staphylococcus aureus than the standard strain.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
기질 | KCTC3108 | APsulloc 331261 | 기질 | KCTC3108 | APsulloc 331261 | ||||
24h | 48h | 24h | 48h | 24h | 48h | 24h | 48h | ||
대조군 | - | - | - | - | 에세쿨린 | + | + | + | + |
글리세롤 | - | - | - | - | 살리신 | + | + | + | + |
에리스리톨 | - | - | - | - | 셀로비오스 | ? | + | + | + |
D-아라비노스 | - | - | - | - | 말토스 | + | + | + | + |
L-아라비노스 | + | + | + | + | 락토스 | + | + | + | + |
리보스 | + | + | + | + | 멜리비오스 | + | + | + | + |
D-자일로스 | - | - | - | - | D-사카로스(수크로스) | + | + | + | + |
L-자일로스 | - | - | - | - | 트레할로스 | + | + | + | + |
아도니톨 | - | - | - | - | 이눌린 | - | - | - | - |
β-메틸-D-자일로스 | - | - | - | - | 멜레치토스 | + | + | + | + |
갈락토스 | + | + | + | + | 라피노스 | - | - | + | + |
글루코스 | + | + | + | + | 아미돈(전분) | - | - | - | - |
프럭토스 | + | + | + | + | 글리코겐 | - | - | - | - |
만노스 | + | + | + | + | 자일리톨 | - | - | - | - |
소르보스 | - | - | - | - | 겐티오비오스 | - | - | + | + |
람노스 | - | - | - | - | D-튜라노스 | + | + | + | + |
덜시톨 | - | - | - | - | D-릭소스 | - | - | - | - |
이노시톨 | - | - | - | - | D-타가토스 | - | - | - | - |
만니톨 | + | + | + | + | D-퓨코스 | - | - | - | - |
소르비톨 | + | + | + | + | L-퓨코스 | - | - | - | - |
α-메틸-D-만노사이드 | ? | + | - | - | D-아라비톨 | ? | - | ? | - |
α-메틸-D-글루코사이드 | - | - | - | - | L-아라비톨 | - | - | - | - |
N-아세틸-글루코사민 | + | + | + | + | 글루콘산 | ? | + | ? | + |
아미그달린 | + | + | + | + | 2-케토글루코네이트 | - | - | - | - |
알부틴 | + | + | + | + | 5-케토글루코네이트 | - | - | - | - |
기질 | KCTC3108 | APsulloc 331263 | 기질 | KCTC3108 | APsulloc 331263 | ||||
24h | 48h | 24h | 48h | 24h | 48h | 24h | 48h | ||
대조군 | - | - | - | - | 에세쿨린 | + | + | + | + |
글리세롤 | - | - | - | - | 살리신 | + | + | + | + |
에리스리톨 | - | - | - | - | 셀로비오스 | ? | + | + | + |
D-아라비노스 | - | - | - | - | 말토스 | + | + | + | + |
L-아라비노스 | + | + | + | + | 락토스 | + | + | + | + |
리보스 | + | + | + | + | 멜리비오스 | + | + | + | + |
D-자일로스 | - | - | - | - | D-사카로스 (수크로스) | + | + | + | + |
L-자일로스 | - | - | - | - | 트레할로스 | + | + | + | + |
아도니톨 | - | - | - | - | 이눌린 | - | - | - | - |
β-메틸-D-자일로스 | - | - | - | - | 멜레치토스 | + | + | + | + |
갈락토스 | + | + | + | + | 라피노스 | - | - | ? | + |
글루코스 | + | + | + | + | 아미돈(전분) | - | - | - | - |
프럭토스 | + | + | + | + | 글리코겐 | - | - | - | - |
만노스 | + | + | + | + | 자일리톨 | - | - | - | - |
소르보스 | - | - | - | - | 겐티오비오스 | - | - | + | + |
람노스 | - | - | - | - | D-튜라노스 | + | + | - | - |
덜시톨 | - | - | - | - | D-릭소스 | - | - | - | - |
이노시톨 | - | - | - | - | D-타가토스 | - | - | - | - |
만니톨 | + | + | + | + | D-퓨코스 | - | - | - | - |
소르비톨 | + | + | + | + | L-퓨코스 | - | - | - | - |
α-메틸-D-만노사이드 | ? | + | - | - | D-아라비톨 | ? | - | - | - |
α-메틸-D-글루코사이드 | - | - | - | - | L-아라비톨 | - | - | - | - |
N-아세틸-글루코사민 | + | + | + | + | 글루콘산 | ? | + | + | + |
아미그달린 | + | + | + | + | 2-케토글루코네이트 | - | - | - | - |
알부틴 | + | + | + | + | 5-케토글루코네이트 | - | - | - | - |
기질 | KCTC3108 | APsulloc 331266 | 기질 | KCTC3108 | APsulloc 331266 | ||||
24h | 48h | 24h | 48h | 24h | 48h | 24h | 48h | ||
대조군 | - | - | - | - | 에세쿨린 | + | + | + | + |
글리세롤 | - | - | - | - | 살리신 | + | + | + | + |
에리스리톨 | - | - | - | - | 셀로비오스 | ? | + | + | + |
D-아라비노스 | - | - | - | - | 말토스 | + | + | + | + |
L-아라비노스 | + | + | + | + | 락토스 | + | + | + | + |
리보스 | + | + | + | + | 멜리비오스 | + | + | + | + |
D-자일로스 | - | - | - | - | D-사카로스 (수크로스) | + | + | + | + |
L-자일로스 | - | - | - | - | 트레할로스 | + | + | + | + |
아도니톨 | - | - | - | - | 이눌린 | - | - | - | - |
β-메틸-D-자일로스 | - | - | - | - | 멜레치토스 | + | + | + | + |
갈락토스 | + | + | + | + | 라피노스 | - | - | + | + |
글루코스 | + | + | + | + | 아미돈(전분) | - | - | - | - |
프럭토스 | + | + | + | + | 글리코겐 | - | - | - | - |
만노스 | + | + | + | + | 자일리톨 | - | - | - | - |
소르보스 | - | - | - | - | 겐티오비오스 | - | - | + | + |
람노스 | - | - | - | - | D-튜라노스 | + | + | + | + |
덜시톨 | - | - | - | - | D-릭소스 | - | - | - | - |
이노시톨 | - | - | - | - | D-타가토스 | - | - | - | - |
만니톨 | + | + | + | + | D-퓨코스 | - | - | - | - |
소르비톨 | + | + | + | + | L-퓨코스 | - | - | - | - |
α-메틸-D-만노사이드 | ? | + | - | - | D-아라비톨 | ? | - | - | - |
α-메틸-D-글루코사이드 | - | - | - | - | L-아라비톨 | - | - | - | - |
N-아세틸-글루코사민 | + | + | + | + | 글루콘산 | ? | + | + | + |
아미그달린 | + | + | + | + | 2-케토글루코네이트 | - | - | - | - |
알부틴 | + | + | + | + | 5-케토글루코네이트 | - | - | - | - |
기질 | KCTC3108 | APsulloc 331269 | 기질 | KCTC3108 | APsulloc 331269 | ||||
24h | 48h | 24h | 48h | 24h | 48h | 24h | 48h | ||
대조군 | - | - | - | - | 에세쿨린 | + | + | + | + |
글리세롤 | - | - | - | - | 살리신 | + | + | + | + |
에리스리톨 | - | - | - | - | 셀로비오스 | ? | + | + | + |
D-아라비노스 | - | - | - | - | 말토스 | + | + | + | + |
L-아라비노스 | + | + | - | - | 락토스 | + | + | + | + |
리보스 | + | + | + | + | 멜리비오스 | + | + | + | + |
D-자일로스 | - | - | + | + | D-사카로스 (수크로스) | + | + | + | + |
L-자일로스 | - | - | - | - | 트레할로스 | + | + | + | + |
아도니톨 | - | - | - | - | 이눌린 | - | - | - | - |
β-메틸-D-자일로스 | - | - | - | - | 멜레치토스 | + | + | + | + |
갈락토스 | + | + | + | + | 라피노스 | - | - | + | + |
글루코스 | + | + | + | + | 아미돈(전분) | - | - | - | - |
프럭토스 | + | + | + | + | 글리코겐 | - | - | - | - |
만노스 | + | + | + | + | 자일리톨 | - | - | - | - |
소르보스 | - | - | - | - | 겐티오비오스 | - | - | + | + |
람노스 | - | - | - | - | D-튜라노스 | + | + | + | + |
덜시톨 | - | - | - | - | D-릭소스 | - | - | - | - |
이노시톨 | - | - | - | - | D-타가토스 | - | - | - | - |
만니톨 | + | + | + | + | D-퓨코스 | - | - | - | - |
소르비톨 | + | + | + | + | L-퓨코스 | - | - | - | - |
α-메틸-D-만노사이드 | ? | + | ? | + | D-아라비톨 | ? | - | - | - |
α-메틸-D-글루코사이드 | - | - | - | - | L-아라비톨 | - | - | - | - |
N-아세틸-글루코사민 | + | + | + | + | 글루콘산 | ? | + | ? | + |
아미그달린 | + | + | + | + | 2-케토글루코네이트 | - | - | - | - |
알부틴 | + | + | + | + | 5-케토글루코네이트 | - | - | - | - |
균주 | 종속명 | % 인덱스 | T 인덱스 |
KCTC | 락토바실러스 플란타룸 | 99.9 | 0.8 |
3108 | 락토바실러스 펜토수스 | 0.1 | 0.29 |
APsulloc 331261 | 락토바실러스 플란타룸 | 99.4 | 0.99 |
락토바실러스 펜토수스 | 0.4 | 0.71 | |
APsulloc 331263 | 락토바실러스 플란타룸 | 98.9 | 0.97 |
락토바실러스 펜토수스 | 0.7 | 0.71 | |
APsulloc 331266 | 락토바실러스 플란타룸 | 99.4 | 0.99 |
락토바실러스 펜토수스 | 0.4 | 0.71 | |
APsulloc 331269 | 락토바실러스 플란타룸 | 99.4 | 0.79 |
락토바실러스 펜토수스 | 0.5 | 0.51 |
효소 | KCTC3108 | APsulloc 331261 | ||
스코어 | 결과 | 스코어 | 결과 | |
대조군 | 0 | - | 0 | - |
알칼라인 포스파타아제 | 0 | - | 1 | - |
에스터라아제 | 1 | - | 2 | - |
에스터라아제 리파아제 | 1 | - | 2 | - |
리파아제 | 0 | - | 2 | - |
류신 아릴아미다아제 | 5 | + | 4 | + |
발린 아릴아미다아제 | 4 | + | 4 | + |
크리스틴 아릴아미다아제 | 1 | - | 2 | - |
트립신 | 0 | - | 0 | - |
α- 키모트립신 | 0 | - | 1 | - |
산 포스파티아제 | 1 | - | 3 | + |
나프톨-AS-BI-포스포하이드로라아제 | 1 | - | 3 | + |
α- 갈락토시다아제 | 1 | - | 3 | + |
β- 갈락토시다아제 | 5 | + | 5 | + |
β- 글루쿠로니다아제 | 1 | - | 2 | - |
β- 글루코시다아제 | 3 | + | 5 | + |
N-아세틸-β-글루코사미니다아제 | 0 | - | 4 | + |
α- 만노시다아제 | 0 | - | 1 | - |
α- 푸코시다아제 | 0 | - | 1 | - |
효소 | KCTC3108 | APsulloc 331263 | ||
스코어 | 결과 | 스코어 | 결과 | |
대조군 | 0 | - | 0 | - |
알칼라인 포스파타아제 | 0 | - | 1 | - |
에스터라아제 | 1 | - | 2 | - |
에스터라아제 리파아제 | 1 | - | 2 | - |
리파아제 | 0 | - | 1 | - |
류신 아릴아미다아제 | 5 | + | 4 | + |
발린 아릴아미다아제 | 4 | + | 4 | + |
크리스틴 아릴아미다아제 | 1 | - | 2 | - |
트립신 | 0 | - | 0 | - |
α- 키모트립신 | 0 | - | 1 | - |
산 포스파티아제 | 1 | - | 3 | + |
나프톨-AS-BI-포스포하이드로라아제 | 1 | - | 3 | + |
α- 갈락토시다아제 | 1 | - | 3 | + |
β- 갈락토시다아제 | 5 | + | 5 | + |
β- 글루쿠로니다아제 | 1 | - | 2 | - |
α-글루코시다아제 | 3 | + | 2 | - |
β- 글루코시다아제 | 3 | + | 5 | + |
N-아세틸-β-글루코사미니다아제 | 0 | - | 4 | + |
α- 만노시다아제 | 0 | - | 1 | - |
α- 푸코시다아제 | 0 | - | 1 | - |
효소 | KCTC3108 | APsulloc 331266 | ||
스코어 | 결과 | 스코어 | 결과 | |
대조군 | 0 | - | 0 | - |
알칼라인 포스파타아제 | 0 | - | 1 | - |
에스터라아제 | 1 | - | 1 | - |
에스터라아제 리파아제 | 1 | - | 1 | - |
리파아제 | 0 | - | 1 | - |
류신 아릴아미다아제 | 5 | + | 4 | + |
발린 아릴아미다아제 | 4 | + | 3 | + |
크리스틴 아릴아미다아제 | 1 | - | 2 | - |
트립신 | 0 | - | 1 | - |
α- 키모트립신 | 0 | - | 1 | - |
산 포스파티아제 | 1 | - | 3 | + |
나프톨-AS-BI-포스포하이드로라아제 | 1 | - | 3 | + |
α- 갈락토시다아제 | 1 | - | 3 | + |
β- 갈락토시다아제 | 5 | + | 5 | + |
β- 글루쿠로니다아제 | 1 | - | 2 | - |
β- 글루코시다아제 | 3 | + | 5 | + |
N-아세틸-β-글루코사미니다아제 | 0 | - | 4 | + |
α- 만노시다아제 | 0 | - | 1 | + |
α- 푸코시다아제 | 0 | - | 0 | - |
효소 | KCTC3108 | APsulloc 331269 | ||
스코어 | 결과 | 스코어 | 결과 | |
대조군 | 0 | - | 0 | - |
알칼라인 포스파타아제 | 0 | - | 1 | - |
에스터라아제 | 1 | - | 1 | - |
에스터라아제 리파아제 | 1 | - | 1 | - |
리파아제 | 0 | - | 1 | - |
류신 아릴아미다아제 | 5 | + | 4 | + |
발린 아릴아미다아제 | 4 | + | 3 | + |
크리스틴 아릴아미다아제 | 1 | - | 2 | - |
트립신 | 0 | - | 1 | - |
α- 키모트립신 | 0 | - | 1 | - |
산 포스파티아제 | 1 | - | 3 | + |
나프톨-AS-BI-포스포하이드로라아제 | 1 | - | 3 | + |
α- 갈락토시다아제 | 1 | - | 3 | + |
β- 갈락토시다아제 | 5 | + | 5 | + |
β- 글루쿠로니다아제 | 1 | - | 2 | - |
β- 글루코시다아제 | 3 | + | 5 | + |
N-아세틸-β-글루코사미니다아제 | 0 | - | 4 | + |
α- 만노시다아제 | 0 | - | 1 | - |
α- 푸코시다아제 | 0 | - | 0 | - |
항생제 | 존(zone) 직경 해석 | |||
성분명 | 농도 | 내성 있음(R) | 중간(I) | 예민함(S) |
암피실린 | 10㎍ | ≤13 | 14-16 | ≥17 |
세프타지딤 | 30㎍ | ≤14 | 15-17 | ≥18 |
클로르암페니콜 | 30㎍ | ≤12 | 13-17 | ≥18 |
시플로플록사신 | 5㎍ | ≤15 | 16-20 | ≥21 |
클린다마이신 | 2㎍ | ≤14 | 15-20 | ≥21 |
에리스로마이신 | 15ug | ≤13 | 14-22 | ≥23 |
겐타마이신 | 120㎍ | ≤6 | 7-9 | ≥10 |
이미페넴 | 10㎍ | ≤13 | 14-15 | ≥16 |
스트렙토마이신 | 10㎍ | ≤11 | 12-14 | ≥15 |
네오마이신 | 30㎍ | ≤12 | 13-16 | ≥17 |
니트로푸란토인 | 300㎍ | ≤14 | 15-16 | ≥17 |
페니실린 | 10U | ≤14 | - | ≥15 |
폴리믹신 B | 300U | ≤8 | 9-11 | ≥12 |
테트라사이클린 | 30㎍ | ≤14 | 15-18 | ≥19 |
트리메토프림 | 5㎍ | ≤10 | 11-15 | ≥16 |
반코마이신 | 30㎍ | ≤14 | 15-16 | ≥17 |
항생제 | KCTC3108 | APsulloc 331261 | APsulloc 331263 | |||
존(mm) | 결과 | 존(mm) | 결과 | 존(mm) | 결과 | |
암피실린 | 29 | S | 27 | S | 31 | S |
세프타지딤 | 23 | S | 16 | I | 15 | I |
클로르암페닐콜 | 24 | S | 24 | S | 25 | S |
시플로플록사신 | - | R | - | R | - | R |
클린다마이신 | 12 | R | 29 | S | 8 | R |
에리스로마이신 | 26 | S | 25 | S | 27 | S |
겐타마이신 | 20 | S | 19 | S | 19 | S |
이미페넴 | 39 | S | 39 | S | 42 | S |
스트렙토마이신 | - | R | - | R | - | R |
네오마이신 | 11 | R | 9 | R | 9 | R |
니트로푸란토인 | - | R | 27 | S | 29 | S |
페니실린 | 24 | S | 18 | S | 19 | S |
폴리믹신 B | - | R | - | R | - | R |
테트라사이클린 | 17 | I | 17 | I | 17 | I |
트리메토프림 | - | R | - | R | - | R |
반코마이신 | - | R | - | R | - | R |
항생제 | KCTC3108 | APsulloc 331266 | APsulloc 331269 | |||
존(mm) | 결과 | 존(mm) | 결과 | 존(mm) | 결과 | |
암피실린 | 29 | S | 21 | S | 21 | S |
세프타지딤 | 23 | S | 10 | R | 10 | I |
클로르암페닐콜 | 24 | S | 22 | S | 22 | S |
시플로플록사신 | - | R | - | R | - | R |
클린다마이신 | 12 | R | 9 | R | 9 | S |
에리스로마이신 | 26 | S | 28 | S | 28 | S |
겐타마이신 | 20 | S | 18 | S | 18 | S |
이미페넴 | 39 | S | 39 | S | 39 | S |
스트렙토마이신 | - | R | - | R | - | R |
네오마이신 | 11 | R | 9 | R | 9 | R |
니트로푸란토인 | - | R | 27 | S | 27 | S |
페니실린 | 24 | S | 12 | R | 12 | R |
폴리믹신 B | - | R | - | R | - | R |
테트라사이클린 | 17 | I | 17 | I | 17 | I |
트리메토프림 | - | R | - | R | - | R |
반코마이신 | - | R | - | R | - | R |
pH | KCTC3108 | APsulloc 331261 | APsulloc 331263 | |||
cfu/ml | 생존율(%) | cfu/ml | 생존율(%) | cfu/ml | 생존율(%) | |
대조군 | 2.9x107 | 100 | 3.8x107 | 100 | 1.9x107 | 100 |
2.0 | 3.0x101 | 0 | 1.0x101 | 0 | <101 | 0 |
2.5 | 2.5x107 | 87.4 | 3.3x107 | 87.7 | 1.4x107 | 76.6 |
3.0 | 3.2x107 | 110.3 | 3.7x107 | 110.3 | 1.8x107 | 94.7 |
3.5 | 2.8x107 | 97.7 | 4.0x107 | 105.3 | 1.8x107 | 93.4 |
pH | KCTC3108 | APsulloc 331266 | APsulloc 331269 | |||
cfu/ml | 생존율(%) | cfu/ml | 생존율(%) | cfu/ml | 생존율(%) | |
대조군 | 2.9x107 | 100 | 5.0x107 | 100 | 5.0x107 | 100 |
2.0 | 3.0x101 | 0 | <101 | 0 | 3.6x102 | 0 |
2.5 | 2.5x107 | 87.4 | 6.0x107 | 118.2 | 5.6x107 | 130.7 |
3.0 | 3.2x107 | 110.3 | - | - | 6.5x107 | 112.7 |
3.5 | 2.8x107 | 97.7 | 5.8x107 | 114.2 | 6.2x107 | 124.0 |
시간 | KCTC3108 | APsulloc 331261 | APsulloc 331263 | |||
(시) | cfu/ml | 생존율(%) | cfu/ml | 생존율(%) | cfu/ml | 생존율(%) |
0 | 3.3x107 | 100 | 6.8x107 | 100 | 3.4x107 | 100 |
1 | 2.9x107 | 86.9 | 6.6x107 | 98 | 2.9x107 | 87.2 |
3 | 2.2x107 | 67.3 | 6.4x107 | 94.6 | 2.7x107 | 79.9 |
시간 | KCTC3108 | APsulloc 331266 | APsulloc 331269 | |||
(시) | cfu/ml | 생존율(%) | cfu/ml | 생존율(%) | cfu/ml | 생존율(%) |
0 | 3.3x107 | 100 | 6.2x107 | 100 | 7.1x107 | 100 |
1 | 2.9x107 | 86.9 | 5.7x107 | 91.4 | 7.6x107 | 107.1 |
3 | 2.2x107 | 67.3 | 5.8x107 | 92.5 | 5.6x107 | 78.8 |
황소 담즙 농도(%) | APsulloc 331261 | APsulloc 331266 | ||
cfu/ml | 생존율(%) | cfu/ml | 생존율(%) | |
0 | 3.3x109 | 100 | 3.3x109 | 100 |
0.3 | 3.2x109 | 96.5 | 3.2x109 | 96.8 |
0.5 | 3.0x109 | 89 | 3.0x109 | 85 |
황소 담즙 농도(%) | KCTC3108 | APsulloc 331263 | APsulloc 331269 | |||
cfu/ml | 생존율(%) | cfu/ml | 생존율(%) | cfu/ml | 생존율(%) | |
0 | 3.3x109 | 100 | 3.3x109 | 100 | 3.3x109 | 100 |
0.3 | 3.2x109 | 97 | 3.2x109 | 111.9 | 3.2x109 | 98.1 |
0.5 | 3.0x109 | 91.9 | 3.0x109 | 106.9 | 3.0x109 | 95.3 |
락트산 | KCTC3108 | APsulloc 331261 | APsulloc 331263 | |||
농도(g/L) | 비율(%) | 농도(g/L) | 비율(%) | 농도(g/L) | 비율(%) | |
D 형 | 11.3 | 72 | 8.9 | 62 | 9.2 | 69 |
L 형 | 4.3 | 28 | 5.5 | 38 | 4.2 | 31 |
합계 | 15.6 | 100 | 14.4 | 100 | 13.4 | 100 |
락트산 | KCTC3108 | APsulloc 331266 | APsulloc 331269 | ||
비율(%) | 농도(g/L) | 비율(%) | 농도(g/L) | 비율(%) | |
D 형 | 72 | 10.2 | 62 | 11.7 | 69 |
L 형 | 28 | 6.3 | 38 | 5.2 | 31 |
합계 | 100 | 16.5 | 100 | 16.9 | 100 |
시험 균주 | 클리어 존의 직경 (mm) | ||
KCTC no. | 균주 | KCTC3108 | APsulloc 331261 |
2008 | 시겔라 프렉스네리 | 26 | 27 |
시험 균주 | 클리어 존의 직경 (mm) | ||
KCTC no. | 균주 | KCTC3108 | APsulloc 331266 |
3710 | 리스테리아 모노사이토젠스 | 16.8 | 19.3 |
3624 | 바실러스 세레우스 | 10.3 | 12.3 |
시험 균주 | 클리어 존의 직경 (mm) | ||
KCTC no. | 균주 | KCTC3108 | APsulloc 331269 |
2514 | 살모넬라 티피무리움 | 8.8 | 9.3 |
1621 | 스태피로코커스 아레우스 | 10 | 10.8 |
Claims (12)
- 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331261 (기탁번호: KCCM11179P) 균주.
- 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331263 (기탁번호: KCCM11180P) 균주.
- 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331266 (기탁번호: KCCM11181P) 균주.
- 락토바실러스 플란타룸(Lactobacillus plantarum) APsulloc 331269 (기탁번호: KCCM11182P) 균주.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서,상기 균주는 차나무(Camellia sinensis) 잎에서 분리된 것임을 특징으로 하는 균주.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서,상기 균주는 내산성능을 가지는 것을 특징으로 하는 균주.
- 제 6 항에 있어서,상기 균주는 pH 2 내지 pH 4에서 0.5시간 내지 5시간 동안 내산성능을 가지는 것을 특징으로 하는 균주.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서,상기 균주는 내담즙산능을 가지는 것을 특징으로 하는 균주.
- 제 1 항에 있어서,상기 균주는 락트산(lactic acid) 생성능을 가지는 것을 특징으로 하는 균주.
- 제 9 항에 있어서,상기 균주는 생성한 락트산 중 D-형이 70% 이하인 락트산 생성능을 가지는 것을 특징으로 하는 균주.
- 제 1 항 내지 제 4 항 중 어느 한 항에 따른 균주 또는 그 배양액을 포함하는 조성물.
- 제 11 항에 있어서,조성물은 발효 식품 조성물인 것을 특징으로 하는 조성물.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/124,483 US20140106435A1 (en) | 2011-06-10 | 2012-06-08 | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
JP2014514809A JP6033290B2 (ja) | 2011-06-10 | 2012-06-08 | チャノキ葉から分離した新規なラクトバチルス・プランタラム |
CN201280038929.2A CN104245920A (zh) | 2011-06-10 | 2012-06-08 | 分离自茶树叶的新型植物乳杆菌 |
HK15100315.1A HK1199904A1 (en) | 2011-06-10 | 2015-01-12 | Novel lactobacillus plantarum isolated from leaves of camelllia sinensis |
US14/670,099 US20150197722A1 (en) | 2011-06-10 | 2015-03-26 | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US14/670,068 US20150197721A1 (en) | 2011-06-10 | 2015-03-26 | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US14/670,121 US20150197723A1 (en) | 2011-06-10 | 2015-03-26 | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US15/018,697 US9782446B2 (en) | 2011-06-10 | 2016-02-08 | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
US15/097,854 US9889167B2 (en) | 2011-06-10 | 2016-04-13 | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
US15/097,877 US9895402B2 (en) | 2011-06-10 | 2016-04-13 | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
US15/097,847 US9895401B2 (en) | 2011-06-10 | 2016-04-13 | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110056468A KR101719197B1 (ko) | 2011-06-10 | 2011-06-10 | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 |
KR1020110056466A KR101769445B1 (ko) | 2011-06-10 | 2011-06-10 | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 |
KR10-2011-0056469 | 2011-06-10 | ||
KR10-2011-0056465 | 2011-06-10 | ||
KR1020110056465A KR101769444B1 (ko) | 2011-06-10 | 2011-06-10 | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 |
KR10-2011-0056466 | 2011-06-10 | ||
KR1020110056469A KR101769446B1 (ko) | 2011-06-10 | 2011-06-10 | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 |
KR10-2011-0056468 | 2011-06-10 |
Related Child Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/124,483 A-371-Of-International US20140106435A1 (en) | 2011-06-10 | 2012-06-08 | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US14/670,099 Division US20150197722A1 (en) | 2011-06-10 | 2015-03-26 | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US14/670,121 Division US20150197723A1 (en) | 2011-06-10 | 2015-03-26 | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US14/670,068 Division US20150197721A1 (en) | 2011-06-10 | 2015-03-26 | Novel lactobacillus plantarum isolated from leaves of camellia sinensis |
US15/018,697 Continuation US9782446B2 (en) | 2011-06-10 | 2016-02-08 | Lactobacillus plantarum isolated from leaves of Camellia sinensis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012169842A2 true WO2012169842A2 (ko) | 2012-12-13 |
WO2012169842A3 WO2012169842A3 (ko) | 2013-03-07 |
Family
ID=47296634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/004569 WO2012169842A2 (ko) | 2011-06-10 | 2012-06-08 | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 |
Country Status (5)
Country | Link |
---|---|
US (8) | US20140106435A1 (ko) |
JP (1) | JP6033290B2 (ko) |
CN (2) | CN104245920A (ko) |
HK (1) | HK1199904A1 (ko) |
WO (1) | WO2012169842A2 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101998210B1 (ko) * | 2012-10-31 | 2019-07-10 | (주)아모레퍼시픽 | 녹차 유산균을 포함하는 피부 각질 제거용 조성물 |
JP2016106918A (ja) * | 2014-12-09 | 2016-06-20 | キンセイマテック株式会社 | 指紋検出用粉末 |
KR102610933B1 (ko) * | 2016-09-27 | 2023-12-08 | (주)아모레퍼시픽 | 락토바실러스 플란타룸의 용출물을 포함하는 모발 또는 두피용 조성물 |
KR102335710B1 (ko) * | 2017-10-31 | 2021-12-07 | (주)아모레퍼시픽 | 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물 |
US11918611B2 (en) | 2018-05-03 | 2024-03-05 | Crigasseni Ag | Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of diarrheal and other microbial diseases |
CN109504630B (zh) * | 2018-12-17 | 2022-03-11 | 吉林中粮生化有限公司 | 一种重组d-乳酸生产植物乳杆菌菌株及利用该菌株生产d-乳酸的方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060005356A (ko) * | 2003-04-04 | 2006-01-17 | 프로비 아베 | 탄닌과 배합된 락토바실러스 플랜타룸 스트레인을 포함하는조성물 및 락토바실러스 플랜타룸 스트레인 |
KR20080102773A (ko) * | 2007-05-22 | 2008-11-26 | 주식회사 이롬 | 이소플라본의 비배당체 전환능력을 가진 신규한 식물 유래유산균인 락토바실러스 플란타럼 |
KR100909452B1 (ko) * | 2007-06-07 | 2009-07-28 | 주식회사 미래자원엠엘 | 신규 유산균 및 이를 함유하는 조성물 |
KR100911115B1 (ko) * | 2007-06-15 | 2009-08-11 | 주식회사 씨티씨바이오 | 내산성, 내담즙산성 및 항균 효과를 가진 신규한 유산균 및 이를 포함하는 조성물 |
KR100973977B1 (ko) * | 2009-07-28 | 2010-08-05 | 안승도 | 신규한 락토바실러스 속 미생물 및 이의 용도 |
KR20100099536A (ko) * | 2009-03-03 | 2010-09-13 | 대상에프앤에프 주식회사 | 신선유지를 위한 식물성 유산균 락토바실러스 플란타륨 dsr ck10, dsr m2 및 이의 용도 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5049440A (en) * | 1989-07-28 | 1991-09-17 | The James River Corporation | Wet wiper natural acid and salt preservative composition |
US5589380A (en) * | 1992-06-05 | 1996-12-31 | University Of Maryland At Baltimore | Isolated DNA molecule encoding SHET1 of Shigella flexneri 2a and mutant Shigella flexneri 2a |
EP1229923A1 (en) * | 1999-11-08 | 2002-08-14 | Ganeden Biotech, Inc. | Inhibition of pathogens by bacillus coagulans strains |
JP4031637B2 (ja) * | 2001-03-07 | 2008-01-09 | 株式会社琉球バイオリソース開発 | 発酵食材、その製造方法、飲食物及び抽出エキス |
DE602004005029T2 (de) * | 2003-05-22 | 2007-11-08 | Synbiotics Ab | Probiotische zusammensetzung mit mindestens zwei milchsäurebakterienstämmen, die zur kolonisierung des magen-darm-trakts fähig sind und in kombination damit die eigenschaften, im darm zu überleben, an den darm zu binden, gegen infektion zu schützen und ballaststoffe zu fermentieren, aufweisen |
AU2003247193A1 (en) * | 2003-07-23 | 2005-02-04 | M.D.Lab Corp. | Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus |
JP2005073549A (ja) * | 2003-08-29 | 2005-03-24 | Oita Technology Licensing Organization Ltd | 乳酸液の製造方法。 |
CA2557834C (en) * | 2004-03-04 | 2012-05-22 | E-L Management Corporation | Skin treatment method with lactobacillus extract |
CN101392223A (zh) * | 2007-09-21 | 2009-03-25 | 北京大北农科技集团有限责任公司 | 一种微生物饲料添加剂菌种的选育方法 |
KR101485182B1 (ko) * | 2007-10-19 | 2015-01-22 | 대상에프앤에프 주식회사 | 병원성 세균의 생육을 억제하는 김치에서 분리한 신규락토바실러스 플란타륨 및 이의 용도 |
KR101621337B1 (ko) * | 2008-04-08 | 2016-05-16 | 라보라뚜아르 엠므2 | 페놀 화합물, 계면활성제 및 용매를 포함하는 수성 소독제 |
CN101302488B (zh) * | 2008-07-04 | 2010-06-30 | 中国科学院微生物研究所 | 一种生产乳酸的方法及其专用植物乳杆菌 |
AU2011209407B2 (en) * | 2010-01-28 | 2014-02-27 | Ab-Biotics S.A. | Probiotic composition for use in the treatment of bowel inflammation |
-
2012
- 2012-06-08 JP JP2014514809A patent/JP6033290B2/ja active Active
- 2012-06-08 CN CN201280038929.2A patent/CN104245920A/zh active Pending
- 2012-06-08 US US14/124,483 patent/US20140106435A1/en not_active Abandoned
- 2012-06-08 WO PCT/KR2012/004569 patent/WO2012169842A2/ko active Application Filing
- 2012-06-08 CN CN202110220150.3A patent/CN113151045A/zh active Pending
-
2015
- 2015-01-12 HK HK15100315.1A patent/HK1199904A1/xx unknown
- 2015-03-26 US US14/670,068 patent/US20150197721A1/en not_active Abandoned
- 2015-03-26 US US14/670,099 patent/US20150197722A1/en not_active Abandoned
- 2015-03-26 US US14/670,121 patent/US20150197723A1/en not_active Abandoned
-
2016
- 2016-02-08 US US15/018,697 patent/US9782446B2/en active Active
- 2016-04-13 US US15/097,854 patent/US9889167B2/en active Active
- 2016-04-13 US US15/097,847 patent/US9895401B2/en active Active
- 2016-04-13 US US15/097,877 patent/US9895402B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060005356A (ko) * | 2003-04-04 | 2006-01-17 | 프로비 아베 | 탄닌과 배합된 락토바실러스 플랜타룸 스트레인을 포함하는조성물 및 락토바실러스 플랜타룸 스트레인 |
KR20080102773A (ko) * | 2007-05-22 | 2008-11-26 | 주식회사 이롬 | 이소플라본의 비배당체 전환능력을 가진 신규한 식물 유래유산균인 락토바실러스 플란타럼 |
KR100909452B1 (ko) * | 2007-06-07 | 2009-07-28 | 주식회사 미래자원엠엘 | 신규 유산균 및 이를 함유하는 조성물 |
KR100911115B1 (ko) * | 2007-06-15 | 2009-08-11 | 주식회사 씨티씨바이오 | 내산성, 내담즙산성 및 항균 효과를 가진 신규한 유산균 및 이를 포함하는 조성물 |
KR20100099536A (ko) * | 2009-03-03 | 2010-09-13 | 대상에프앤에프 주식회사 | 신선유지를 위한 식물성 유산균 락토바실러스 플란타륨 dsr ck10, dsr m2 및 이의 용도 |
KR100973977B1 (ko) * | 2009-07-28 | 2010-08-05 | 안승도 | 신규한 락토바실러스 속 미생물 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
US20160228478A1 (en) | 2016-08-11 |
US9895402B2 (en) | 2018-02-20 |
US20150197721A1 (en) | 2015-07-16 |
US20150197722A1 (en) | 2015-07-16 |
HK1199904A1 (en) | 2015-07-24 |
WO2012169842A3 (ko) | 2013-03-07 |
US9782446B2 (en) | 2017-10-10 |
US20160151434A1 (en) | 2016-06-02 |
US20160228480A1 (en) | 2016-08-11 |
US20160228479A1 (en) | 2016-08-11 |
JP6033290B2 (ja) | 2016-11-30 |
US20150197723A1 (en) | 2015-07-16 |
US9895401B2 (en) | 2018-02-20 |
JP2014516567A (ja) | 2014-07-17 |
US20140106435A1 (en) | 2014-04-17 |
CN113151045A (zh) | 2021-07-23 |
US9889167B2 (en) | 2018-02-13 |
CN104245920A (zh) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020075949A1 (ko) | 신규한 락토바실러스 플란타룸 균주 atg-k2, atg-k6 또는 atg-k8, 이를 포함하는 질염의 예방 또는 치료용 조성물 | |
WO2012169842A2 (ko) | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 | |
WO2013151361A1 (ko) | 신규 바실러스 서브틸리스 | |
WO2011010770A1 (ko) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 | |
WO2012105805A2 (en) | Probiotics for biological control against vibrio sp. | |
WO2014069874A1 (ko) | 녹차 유산균을 포함하는 피부 각질 제거용 조성물 | |
WO2019088379A1 (ko) | 신규 유산균 및 이의 용도 | |
WO2020091312A1 (ko) | 프로바이오틱스를 유효성분으로 포함하는 알코올성 장손상 예방 또는 치료용 조성물 | |
KR101719197B1 (ko) | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 | |
WO2019027073A1 (ko) | 바실러스 서브틸리스 및 바실러스 리체니포미스를 포함하는 사료 첨가제, 상기 첨가제를 포함하는 사료 조성물 및 상기 사료첨가제의 제조 방법 | |
WO2017047962A1 (ko) | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능 장애의 예방, 개선 또는 치료용 조성물 | |
WO2023055188A1 (ko) | 신규 프로바이오틱스 및 이의 용도 | |
WO2019013382A1 (ko) | 바실러스 서브틸리스 및 바실러스 리체니포미스를 포함하는 사료 첨가제, 상기 첨가제를 포함하는 사료 조성물 및 상기 사료첨가제의 제조 방법 | |
WO2022039561A1 (ko) | 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물 | |
WO2019088421A1 (ko) | 녹차 유래 유산균을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 | |
KR102001990B1 (ko) | 면역 활성, 항바이러스 활성 및 프로바이오틱스 특성을 갖는 페디오코커스 애시디락티시 srcm102615 균주 및 이의 용도 | |
WO2017026635A1 (ko) | 신규한 락토바실러스 속 미생물 및 이를 포함하는 동물 사료용 조성물 | |
WO2023229394A1 (ko) | 체지방 감소 활성을 갖는 인체 유래 락토바실러스 파라카제이 또는 락토바실러스 플란타룸 균주 및 이를 포함하는 혼합 조성물 | |
WO2022231178A1 (ko) | 신규한 락토바실러스 퍼멘텀 atg-v5 균주 또는 이를 포함하는 면역증강용 조성물 | |
KR101769444B1 (ko) | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 | |
WO2022158641A1 (ko) | 신규 리조푸스 올리고스포러스 균주 및 이를 포함하는 항균 조성물 | |
WO2021040086A1 (ko) | 신규한 유산균, 이를 포함하는 조성물 및 건강기능식품 | |
WO2019209086A1 (ko) | 류코노스톡 메젠테로이드 균주 및 이의 용도 | |
KR101769446B1 (ko) | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 | |
KR101769445B1 (ko) | 차나무 잎에서 분리한 신규 락토바실러스 플란타룸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12797118 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14124483 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014514809 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112 (1) EPC, FORM 1205A DATED 27-03-2014 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 27-03-2014 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12797118 Country of ref document: EP Kind code of ref document: A2 |